Clearpoint Neuro is trading 11.4% down at $9.00 in pre-market on November 5; the available evidence does not confirm a cause for the decline.
- Third-quarter revenue grew, while the loss widened and full-year revenue guidance narrowed. Results were announced October 28 and do not establish the reason for this morning’s decline.
- The November 3 investor-investigation announcement was prior news, and no source found directly links it to the pre-market move.